Enbrel market seen topping $22 billion by 2030

The global Enbrel market is projected to grow from $16.8 billion in 2025 to $17.8 billion in 2026, with the market research firm forecasting continued expansion to $22.1 billion by 2030. Rising autoimmune disease diagnoses, biosimilar competition and broader biologic use are reshaping the outlook.

Why it matters: - The Enbrel market is expanding as more patients are diagnosed with autoimmune diseases and more physicians use biologic therapies in routine care. - The forecast points to continued demand for etanercept-based treatment even as biosimilars and lower-cost biologic options increase pressure on the category.

What happened: - The Business Research Company published its Enbrel Market Research Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the Enbrel market will rise from $16,825.42 million in 2025 to $17,802.88 million in 2026, a 5.8% CAGR. - The report projects the market will reach $22,054.02 million by 2030, growing at a 5.5% CAGR. - Enbrel, also known as etanercept, is a prescription biologic used to treat autoimmune disorders by suppressing immune activity. - The drug works by blocking tumor necrosis factor, or TNF, a protein tied to inflammation in diseases such as rheumatoid arthritis and psoriasis.

The details: - The report ties 2026 growth to rising autoimmune disease prevalence, the clinical effectiveness of TNF inhibitors, wider use of biologics in rheumatology, established biologic reimbursement systems, and greater physician familiarity with etanercept therapies. - The forecast period includes expected pressure from biosimilars, stronger demand for cost-effective biologic alternatives, growth in emerging healthcare regions, expansion of specialty pharmacy distribution, and ongoing biologic drug innovation. - The report says key trends will include wider biosimilar adoption, more patient-friendly drug delivery methods, greater focus on chronic autoimmune disease management, expansion of combination therapies, and improved cold-chain distribution. - The report identifies autoimmune disease prevalence as a major driver because the patient pool for therapies like Enbrel is growing. - Arthritis Australia reported in February 2024 that about 562,378 Australians are expected to live with rheumatoid arthritis by 2025, representing 14% of the arthritis population. - The report says Enbrel helps reduce symptoms and prevent ongoing tissue damage in affected patients. - North America held the largest Enbrel market share in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The report includes links for a free sample and the full market report. - Download a free sample of the Enbrel market report. - View the full Enbrel market report.

Between the lines: - The forecast suggests the market is shifting from broad growth to a more competitive phase, where biosimilars and reimbursement dynamics may shape pricing and share gains. - North America’s lead suggests the market still depends heavily on mature healthcare systems, while Asia-Pacific’s faster growth signals future opportunity is moving toward regions with expanding access. - The report’s emphasis on delivery methods, cold-chain logistics and combination therapies points to competition beyond the molecule itself.

What's next: - The market is expected to keep growing through 2030, but the pace will likely depend on biosimilar uptake, regional access expansion and continued demand for chronic autoimmune disease treatment. - The Business Research Company is promoting its 2026 report package with updated forecasting tools and additional market analysis features.